Engineered CD40 Antibody Eliminates Metastatic Cancers in Two Patients After Single-Tumor Injection, Sparking Expanded Trials
A redesigned CD40 agonist antibody injected into a single tumor triggered body-wide immune responses that eliminated all metastases in two patients, with nearly 200 now enrolled in follow-up trials.
Overview
A phase 1 clinical trial led by researchers at Rockefeller University has demonstrated that a redesigned cancer immunotherapy drug, injected directly into a single tumor, can trigger a systemic immune response that eliminates cancer throughout the body. Two of twelve patients with metastatic cancers achieved complete remission, with all visible tumors disappearing after treatment with the engineered CD40 agonist antibody known as 2141-V11. The results, published in Cancer Cell, have prompted expanded trials now enrolling nearly 200 patients across multiple cancer types.
What We Know
The drug, 2141-V11, was engineered in 2018 by immunologist Jeffrey V. Ravetch and his team at Rockefeller University. CD40 is a receptor on immune cells that, when activated, can stimulate anti-tumor immune responses. Previous attempts to exploit this pathway through intravenous CD40 agonist antibodies were hampered by severe systemic toxicity, including dangerous liver inflammation and blood platelet depletion.
Ravetch’s team took a different approach on two fronts. First, they redesigned the antibody’s Fc region with five specific mutations to increase binding affinity to a particular Fc receptor (FcgammaRIIB), which enhances the crosslinking needed for effective CD40 activation. Laboratory studies showed this made the antibody approximately ten times more effective at triggering immune attacks against tumors, according to ScienceDaily. Second, they delivered the drug via direct injection into accessible tumors rather than through the bloodstream.
The phase 1 trial (NCT04059588) enrolled 12 patients with metastatic cancers who had exhausted conventional options, having received a median of five prior lines of therapy. The cohort included seven breast cancer patients, three melanoma patients, and two renal cell carcinoma patients, according to the study published in PMC.
Of ten evaluable patients, six experienced tumor shrinkage, two achieved complete remission, and the overall disease control rate reached 80 percent. Among the injected lesions specifically, 35.7 percent showed responses, while 25 percent of non-injected lesions also responded, demonstrating what oncologists call an abscopal effect, as reported in the PMC-published study.
The two complete remission cases were particularly striking. One melanoma patient had dozens of metastatic tumors on her leg and foot. Researchers injected only a single tumor on her thigh, and after multiple injection cycles, all other tumors disappeared, according to ScienceDaily. The second patient, with breast carcinoma, saw tumors in the skin, liver, and lungs eliminated from a single skin injection site.
Tissue analysis of responding tumors revealed the formation of tertiary lymphoid structures, organized clusters of immune cells that the researchers described as resembling lymph nodes forming directly within the tumor tissue. These structures were characterized by increased CD8+ and CD4+ T-cell infiltration and CD20+ B-cell centers, according to the Cancer Cell paper.
Critically, the treatment produced only mild side effects. All adverse events were grade 1 or 2, with fever (42 percent of patients), injection-site reactions (25 percent), and chills (25 percent) being the most common. No dose-limiting toxicities were observed, and the maximum tolerated dose was not reached, according to the PMC-published study. The severe thrombocytopenia and hepatotoxicity that plagued earlier CD40 drugs were notably absent.
What We Don’t Know
The trial’s small size of twelve patients means the results, while promising, require significant validation. It remains unclear why some patients responded completely while others with similar cancer types did not. The researchers have not yet identified reliable biomarkers that predict which patients will benefit from the treatment.
The durability of the complete remissions is also uncertain. While the results are encouraging, longer follow-up is needed to determine whether the immune responses persist or whether cancers eventually recur. The mechanism by which a local injection triggers a systemic response, while observed, is not yet fully understood.
What Comes Next
Ravetch’s group is now collaborating with scientists at Memorial Sloan Kettering Cancer Center and Duke University to further evaluate 2141-V11 in expanded trials. Current phase 1 and phase 2 studies are testing the therapy against several difficult-to-treat cancers, including bladder cancer, prostate cancer, and glioblastoma, with nearly 200 patients enrolled across these studies, according to ScienceDaily.
The approach of combining Fc-engineered antibodies with intratumoral delivery represents a broader shift in cancer immunotherapy toward localized treatments that can generate systemic immune responses while avoiding the toxicity of intravenous administration. If the expanded trials confirm the phase 1 findings, 2141-V11 could offer a new treatment pathway for patients with metastatic cancers who have run out of standard options.